Waters Corporation
0LTI.L
London Stock Exchange369.17
USD
-6.97
- -
Waters Corporation
0LTI.L
(London Stock Exchange)
Recent
price
369.17
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Waters Corporation (NYSE: WAT; LSE: 0LTI) develops, manufactures, markets and services analytical instruments, software and precision chemistries for life sciences, materials, food and environmental applications worldwide. The company, founded in 1958 and headquartered in Milford, Massachusetts, operates through two segments, Waters and TA Instruments; the Waters segment provides liquid chromatography (LC) systems including ultra performance LC (UPLC), high performance LC (HPLC) and integrated LC-mass spectrometry (MS) solutions such as ACQUITY UPLC systems, Alliance HPLC systems and Xevo MS instruments, alongside mass spectrometry systems, gas chromatography (GC), sample preparation products like solid-phase extraction cartridges and filtration devices, chromatography columns and consumables including vials, plates and chemistry standards, informatics and laboratory software for data management, workflow automation and compliance, laboratory automation equipment and services encompassing maintenance, training and upgrades; the TA Instruments segment supplies thermal analysis, rheology and mechanical testing instruments for materials characterization. Waters maintains manufacturing facilities in the United States, Ireland and the United Kingdom, with sales and operations spanning more than 100 countries across the Americas, Europe, Asia and other regions, serving pharmaceutical, biotechnology, academic, chemical, environmental and food safety customers. In July 2025, Waters announced a definitive agreement to combine with Becton, Dickinson and Company's (BD) Biosciences and Diagnostic Solutions business in a $17.5 billion tax-efficient Reverse Morris Trust transaction expected to close in the first quarter of 2026, creating a life science and diagnostics leader with pro forma 2025 sales of approximately $6.5 billion, a combined market of $40 billion and enhanced capabilities in high-growth markets through complementary technologies and R&D; the deal positions BD shareholders to own about 39% of the combined entity while Waters assumes around $4 billion in debt and BD receives a $4 billion cash distribution.